-
公开(公告)号：US07576115B2
公开(公告)日：2009-08-18
申请号：US11837659
申请日：2007-08-13
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/415 , C07D231/10
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1是键，CR10R11，氧原子，硫原子或NR12，X是OR13，SR13或NR14NR15，R2是氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫原子 原子或NR 23，并且R 3是C 12-14芳基，互变异构体，前药或化合物或其溶剂合物的药学上可接受的盐。
-
公开(公告)号：US20130012708A1
公开(公告)日：2013-01-10
申请号：US13613195
申请日：2012-09-13
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： C07D409/12 , C07D333/32 , C07D409/14 , C07D417/12 , C07D413/12 , C07D231/18 , C07D403/12
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US08318796B2
公开(公告)日：2012-11-27
申请号：US12492435
申请日：2009-06-26
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/38 , C07D333/12
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20110077290A1
公开(公告)日：2011-03-31
申请号：US12492435
申请日：2009-06-26
申请人： Shingo OWADA , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo OWADA , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/381 , C07D333/32 , A61P7/04
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1为键，CR10R11，氧原子，硫原子或NR12，X为OR13，SR13或NR14NR15，R2为氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫 原子或NR 23，并且R 3是该化合物或其溶剂合物的C2-14芳基，互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20060094694A1
公开(公告)日：2006-05-04
申请号：US11294609
申请日：2005-12-06
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/675 , C07D261/12 , C07D231/08 , A61K31/42 , A61K31/4152
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。
-
公开(公告)号：US07351841B2
公开(公告)日：2008-04-01
申请号：US11294609
申请日：2005-12-06
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： C07D333/12 , C07D333/16 , C07D333/18 , C07D333/20 , C07D333/32 , C07D333/34 , A61K31/381
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。
-
公开(公告)号：US07968542B2
公开(公告)日：2011-06-28
申请号：US11994502
申请日：2006-07-13
申请人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： C07D401/14 , C07D409/14 , C07D413/14 , A61K31/381 , A61P7/00
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20110092496A1
公开(公告)日：2011-04-21
申请号：US12955477
申请日：2010-11-29
申请人： Katsuaki MIYAJI , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki MIYAJI , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： A61K31/5377 , C07D405/12 , C07D409/12 , C07D233/96 , C07D231/10 , C07D333/22 , C07D261/08 , C07D411/12 , A61K31/497 , A61K31/4436 , A61K31/4178 , A61K31/4155 , A61K31/422 , A61K31/4025 , A61K31/381 , A61P7/00
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20090131659A1
公开(公告)日：2009-05-21
申请号：US11721786
申请日：2005-12-14
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
IPC分类号： C07D413/12 , C07D409/14
CPC分类号： C07D231/18
摘要： The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective.A compound represented by the formula (1): wherein A, B, R1, L1, R2, L2, L3, Y, L4, R3 and X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 本发明提供了可用于预防，治疗或缓解血小板生成素受体活化有效的疾病的化合物。 由式（1）表示的化合物：其中A，B，R1，L1，R2，L2，L3，Y，L4，R3和X与说明书中定义的相同，互变异构体，前药或药学上可接受的盐 化合物或其溶剂合物。
-
公开(公告)号：US20090118500A1
公开(公告)日：2009-05-07
申请号：US11994502
申请日：2006-07-13
申请人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： C07D495/04 , C07D409/12 , C07D409/02
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.078 秒)
